It should be recommended to support further clinical testing of pyrotinib in NSCLC patients with HER2 exon 20 mutations to determine its impact on the OS, RR, DOR as well as the safety and toxicity. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.